Skip to main content
OpenTrials
Completed

NCT Number: NCT05442177

Clinical Observation of Integrated Chinese Medicine With Western Medicine for the Reduction of Chemotherapy-induced Hematologic Toxicity

We conducted an observational study to investigate the effectiveness and safety of Integrated Chinese Medicine With Western Medicine for bone marrow suppression induced by chemotherapy in patients with cancer. The TCM constitution and pulse diagnosis was also observed in the study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myelosuppression Neoplasms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

About this study

Patients with cancer under chemotherapy and integrated Western and Chinese medicine were enrolled in this observational study. The assessment of radial pressure pulse (RPP) was performed before and after chemotherapy. The correlation between the spectral energy (SE0-10 Hz, SE10-50 Hz, and SE13-50 Hz) of the RPP at six diagnosis positions and the blood cell counts before and after chemotherapy were analyzed.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with cancer diagnosed through pathological histology
  • Patients with cancer under chemotherapy and Integrated Chinese Medicine With Western Medicine
  • Patients with an Eastern Cooperative Oncology Group Performance score of 0-2
  • Patients having normal liver and kidney functions and electrocardiography and eligible for chemotherapy with normal bone marrow hematopoietic function
  • Patients who were voluntarily involved in this study

Exclusion criteria

  • Cases that did not meet the inclusion criteria
  • Patients who could not cooperate with pulse diagnosis
  • Patients with underlying diseases such as chronic obstructive pulmonary disease, cardiac failure, chronic renal failure, cirrhosis, etc.
  • Patients with severe infection
  • Patients with severe cachexia

Treatment and study plan

Chemotherapy and Integrated Chinese Medicine With Western Medicine for cancer treatment

Procedure

Primary outcomes

  1. Chemotherapy-induced Hematologic Toxicity

    Time frame: one month

    the blood cell count before and after chemotherapy was collected for measurement of severity of myelosuppression

Sponsors and collaborators

Lead sponsor

Taichung Tzu Chi Hospital

Other

Registry information

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Jul 1, 2022
Registry last updated
Jul 1, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.